ADIL
$1.89
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.
Intraday
Recent News
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls
CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls
Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Tuesday received the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held in July. The minutes provide the FDA's formal input into the AD04 Phase 3 adaptive clinical trial design and broader clinical development strategy. The objective for the EOP2 Meeting was to align with the FDA on the design of the Phase 3 clinical development program for AD04, the company's lead investigational drug, a
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Thermo Fisher Scientific (TMO) Inks Deal to Manufacture Adial Pharmaceuticals ADO4
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of Goldman Sachs’ top healthcare stock picks. On June 25, the company confirmed it had inked a strategic partnership with Adial Pharmaceuticals (NASDAQ:ADIL). Under the terms of the agreement, Thermo Fisher is to become the Contract Development and Manufacturing Organization (CDMO) for AD04 Drug products. The product is […]